Clinical Trial Update: A Clinical Trial of Panitumumab in Combination With FOLFIRI Chemotherapy as Second Line Treatment in Subjects With Metastatic Colorectal Cancer Expressing Wild-type KRAS and Who Had Progressed ≥ 6 Months After the Last Dose of the First Line Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating panitumumab in combination with FOLFIRI as second-line therapy for metastatic colorectal cancer with wild-type KRAS after prog…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• 5-fluorouracil (5-FU) (5-fluorouracil)
• Irinotecan (Irinotecan)
• Panitumumab (panitumumab)

Snippet

Sponsor: Associacio catalana per a la recerca oncologica i les seves implicacions sanitaries i socials | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: UNKNOWN